PEOPLE

Wilex (Munich) has ActivX Biosciences, and was previously vice announced that Paul president at Merck Research Laboratories. In Bevan, formerly research addition, Dr. Kozarich is a biotechnology director at Xenova professor at the Scripps Research Institute. Therapeutics and a member of Xenova Ortec International (New York) has Group’s executive board, announced the promotion of Ron Lipstein to has been appointed the company’s head of the position of CEO. Mr. Lipstein is a founder research and development and a member of of Ortec and has served as CFO since its the executive board. Dr. Bevan was most inception and as vice chairman for the past recently CEO of PharmAssociates, a pharma- two years. He will continue in his role as vice ceutical consulting firm that he founded in chairman. In addition, Costa Papastephanou, 1999. president of Ortec, will also assume the posi- tion of COO. Steven Katz, who has served as Stéphane Boissel has been appointed chief CEO since Ortec’s founding, will continue to financial officer at Innate Pharma (Marseille, serve as chairman of the board. France). Mr. Boissel has spent the past seven years with Groupe Lazard in France, Aton Pharma (Tarrytown, NY) has Singapore, and Hong Kong, and was most announced the appointment of Carolyn M. recently director of investments at Eurazeo, a Paradise as senior vice president and chief member of the Lazard group. medical officer. Dr. Paradise previously served as executive vice president, clinical Joseph R. Chinnici has been elected to the operations and regulatory affairs and chief board of directors at Guilford medical officer at Cell Therapeutics. http://www.nature.com/naturebiotechnology Pharmaceuticals (Baltimore, MD), as well as to the board’s audit committee. He currently Nabi Biopharmaceuticals (Boca Raton, FL) serves as senior vice president, finance and has named Henrik Rasmussen to the posi- CFO at CIENA Corp. Mr. Chinnici replaces tion of vice president, clinical and regulatory David P. Wright, who recently resigned his affairs, a newly created position. Dr. position on Guilford’s board. Rasmussen joins the company from GenVec, where he was senior vice president of clinical Juvaris BioTherapeutics (Pleasanton, CA), a and regulatory affairs. Prior to that, he was privately held therapeutic vaccine company, senior vice president of clinical research and has announced the appointment of Martin regulatory affairs at British Biotech. D. Cleary as chairman, president, and CEO. From 1999 to 2002, Mr. Cleary served as Lauren P. Silvernail has joined ISTA president, CEO, and a director of Genteric, Pharmaceuticals (Irvine, CA) as CFO and and was previously cofounder, president, vice president of corporate development. © Group 2003 Nature Publishing and CEO of CardioGene Therapeutics. Prior to joining the company, Ms. Silvernail spent eight years at Allergan, most recently PhageTech (Montreal, QC, Canada) has as vice president of business development. named Daniel Delorme, formerly vice presi- dent of medicinal chemistry at MethylGene, Auxilium Pharmaceuticals (Norristown, PA) as vice president of chemistry. Prior to join- has named Stephen G. Sudovar, president ing MethylGene in 1998, Dr. Delorme was and CEO of EluSys Therapeutics and former associate director of medicinal chemistry at president of Roche Laboratories, to its board AstraZeneca (Montreal). PhageTech also of directors. announced the appointment of Michel Harpin, formerly senior marketing advisor William Spickler has joined Angiogenix of life sciences at Solidarity Fund QFL, as (Burlingame, CA) as vice president of phar- director of business development. maceutical development. Most recently, he served as the senior medical director for Odyssey Thera (San Ramon, CA) has named XOMA, where he was responsible for clinical Louis Ignarro to its board of directors. Dr. development programs in the cardiovascular Ignarro is a professor in the department of and rheumatology therapeutic areas. molecular and medical at the UCLA School of Medicine and recipient of Doug Williams has been appointed chair- the 1998 in or man of the board of directors of startup Medicine. Amnis (Seattle, WA). Previously executive vice president and chief technology officer at John W. Kozarich has been elected to the Immunex, Dr. Williams became senior vice board of directors of Ligand president, Washington site leader for Amgen Pharmaceuticals (San Diego, CA). Dr. upon its acquisition of Immunex. He has Kozarich is president, CEO, and CSO of been a member of Amnis’s board since 2000.

www.nature.com/naturebiotechnology • APRIL 2003 • VOLUME 21 • nature biotechnology 457